TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11786584
Drug: Isotretinoin added
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isotretinoin added to hormonal therapy (arm 1)
Study: 11786584
Drug: Hormonal therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal therapy alone (arm 2)
Study: 1099047
Drug: Contingent administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Contingent administration of naloxone (N-allylnoroxymorphone) 500-2000 mg daily
Study: 31828863
Drug: Wheat germ
Normalized name: Wheat Germ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat germ (WG) supplementation, 20g daily for 12 weeks
Study: 19543080
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg/day) upon awakening
Study: 15286880
Drug: Gatifloxacin IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin IV followed by oral administration
Study: 15286880
Drug: Ceftriaxone IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone IV alone or in combination with erythromycin IV, followed by clarithromycin PO
Study: 9437184
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg daily soy isoflavones (45 mg genistein)
Study: 2825745
Drug: Dipyridamole 150/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 150/200 mg single doses
Study: 2825745
Drug: Dipyridamole 150/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 150/200 mg multiple doses (twice daily for 11 days)
Study: 2825745
Drug: Dipyridamole (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (various doses)
Study: 2825745
Drug: Dipyridamole (150/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (150/200 mg)
Study: 20947492
Drug: Dose-matched therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched therapeutic exercise (DMTE)
Study: 1347857
Drug: CGRP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CGRP infusion at 0.6 micrograms/min for 4 hours, then up to a maximum of 10 days
Study: 2988107
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g coarse wheat bran
Study: 2988107
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g placebo bran
Study: 19054552
Drug: Tasimelteon 20
Normalized name: tasimelteon 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasimelteon 20 mg
Study: 30353049
Drug: Complete Decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Decongestive Therapy including manual lymphatic drainage (T+MLD)
Study: 30353049
Drug: Complete Decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete Decongestive Therapy without manual lymphatic drainage (T-MLD)
Study: 24154667
Drug: Intravenous lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lorazepam (LRZ; 0.01 mg/kg)
Study: 22198049
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (MA) plus l-carnitine, celecoxib, and antioxidants (arm 1)
Study: 17385970
Drug: Psychological preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological preparation for surgery
Study: 17984132
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (1 x 10(6) cells/0.1 mL, n = 9)
Study: 17984132
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (2 x 10(6) cells/0.1 mL, n = 10)
Study: 17984132
Drug: Control (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.1 mL autologous plasma/injection, n = 9)
Study: 6438683
Drug: Sulpiride (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (800 mg/day)
Study: 6438683
Drug: Chlorpromazine (CPZ)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (CPZ) (400 mg/day)
Study: 31256717
Drug: High medication
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High medication burden
Study: 31256717
Drug: Intensive vs
Normalized name: VS-4718
DrugBank: VS-4718 (DB15273)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive vs Standard treatment
Study: 31256717
Drug: Medication burden
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication burden
Study: 29744647
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow grafting (percutaneous mesenchymal cell injection)
Study: 27071759
Drug: Duloxetine (55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (55 mg/day, range 40-60 mg/day)
Study: 27071759
Drug: Sertraline (146
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (146 mg/day, range 50-200 mg/day)
Study: 20202239
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment with 0.2% betamethasone-hyaluronidase cream twice a day for 8 weeks
Study: 11821087
Drug: No Hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No Hormone Replacement Therapy
Study: 7726526
Drug: Cloxacillin 2
Normalized name: cloxacillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloxacillin 2 g every 4 hours and Gentamicin 1.5 mg/kg every 8 hours for 2 weeks (Group A)
Study: 7726526
Drug: Teicoplanin 10
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 10 mg/kg/12 hours on days 1-3, 6 mg/kg/12 hours on days 4-7, and 7 mg/kg/24 hours on day 8 (Group B)
Study: 30268346
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) promethazine
Study: 30268346
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Ondansetron
Study: 23819659
Drug: methylprednisolone 80 mg + 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 80 mg + 5 mL of levobupivacaine without epinephrine + 3 mL of 0.9% saline solution
Study: 23819659
Drug: methylprednisolone 80 mg + 8 mL
Normalized name: methylprednisolone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylprednisolone 80 mg + 8 mL of 0.9% saline solution
Study: 16015691
Drug: Itopride 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 150 mg t.i.d.
Study: 16015691
Drug: Itopride 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itopride 300 mg t.i.d.
Study: 6401908
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 80 mg 4 times a day)
Study: 6401908
Drug: Pindolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (5 to 10 mg 2 times a day)
Study: 29573460
Drug: Poor self-rated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor self-rated oral health in older age group
Study: 29573460
Drug: Poor self-rated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor self-rated oral health in Guarani peoples
Study: 27114074
Drug: Lenalidomide/dexamethasone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide/dexamethasone plus high-dose chemotherapy and autologous stem cell transplantation followed by lenalidomide maintenance
Study: 19124377
Drug: Erdosteine 300
Normalized name: erdosteine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erdosteine 300 mg
Study: 15755632
Drug: OncoVAX therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OncoVAX therapy (active specific immunotherapy using autologous tumor cells with BCG vaccine)
Study: 15755632
Drug: OncoVAX therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: OncoVAX therapy
Study: 8748726
Drug: Standardized immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized immunotherapy (IT) (Alpare)
Study: 22201324
Drug: Optimized aspheric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized aspheric treatment zone ablation (OATz)
Study: 17976843
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) with and without defibrillator back‐up
Study: 12008991
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (n=54) attended two group nutrition education classes and one individual diet counseling session led by the same dietitian.
Study: 10321414
Drug: Eprosartan 600
Normalized name: eprosartan 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan 600 mg once daily
Study: 8735463
Drug: Dermal exposure
Normalized name: Dermal-Soothe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermal exposure to 86 mg/m3 cis-1,3-DCP for 45 minutes
Study: 1767904
Drug: Midazolam IV
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam IV solution 10 mg
Study: 6412612
Drug: alfentanil 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 0.75 mg
Study: 6412612
Drug: fentanyl 0.25
Normalized name: bupivacaine-fentanyl 0.25%-20 mcg/mL-0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 0.25 mg
Study: 29545067
Drug: Natalizumab 300
Normalized name: natalizumab 300 MG in 15 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natalizumab 300 mg intravenous every 4 weeks for 2 years
Study: 23203322
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (MPA, 10 mg/d for 10 days per cycle)
Study: 23203322
Drug: Norethisterone (NET,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone (NET, 15 mg/d for 10 days per cycle)
Study: 14623537
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (anastrozole + tamoxifen)
Study: 10928757
Drug: Bacitracin ointment
Normalized name: Bacitracin Ointment
DrugBank: Bacitracin (DB00626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bacitracin ointment (or erythromycin/gentamicin if resistant to bacitracin) applied to the lid margin
Study: 3894250
Drug: Acebutolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (100 mg intravenous perfusion over 24 hr or 600 mg orally, followed by 1200 mg/day orally)
Study: 29148629
Drug: Mouth rinse
Normalized name: Ulcerease 0.6 % Mouth Rinse
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouth rinse with carbohydrate solution (MRCS)
Study: 22622138
Drug: Baseline PIIINP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PIIINP levels <0.72 U/mL
Study: 22622138
Drug: Baseline PIIINP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline PIIINP levels >0.72 U/mL
Study: 20860916
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of mycophenolate mofetil 500 mg (Suprimun®)
Study: 20860916
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of mycophenolate mofetil 500 mg
Study: 16687365
Drug: Mecamylamine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecamylamine (6 mg/day)
Study: 31037806
Drug: Low-volume resistance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume resistance training (6 months, twice a week)
Study: 31037806
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintained pharmacological treatments)
Study: 23421600
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 3 g/day with riluzole 100 mg/day
Study: 23421600
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 g/day with riluzole 100 mg/day
Study: 9098093
Drug: Oil-based Q10
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-based Q10 (90 mg/d)
Study: 9098093
Drug: Granular Q10
Normalized name: SAXIFRAGA GRANULATA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granular Q10 (90 mg/d)
Study: 9098093
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Q10 (single dose)
Study: 8218955
Drug: Transnasal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transnasal administration of butorphanol (2 mg)
Study: 8218955
Drug: Sublingual administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual administration of butorphanol (2 mg)
Study: 8218955
Drug: Buccal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal administration of butorphanol (2 mg)
Study: 8218955
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of butorphanol (2 mg)
Study: 3700691
Drug: Cimetidine 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1,200 mg/d
Study: 4085354
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg/d
Study: 28743757
Drug: Erythropoiesis-stimulating agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoiesis-stimulating agent (ESA) treatment
Study: 22269382
Drug: Screening arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Screening arm (PSA every 4 years, prostate biopsy when PSA ≥3 ng/ml)
Study: 17513813
Drug: Active specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active specific immunotherapy with allogeneic melanoma lysates and low-dose interferon alfa-2b (IFN-alpha-2b) for 2 years
Study: 17513813
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alfa-2b for 1 year
Study: 12243812
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation with concomitant and maintenance chemotherapy (96% of patients)
Study: 8586126
Drug: OKY-046 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY-046 (400 mg/day)
Study: 823084
Drug: Butalamine hydrochloride
Normalized name: butalamine hydrochloride
DrugBank: Butalamine (DB13681)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butalamine hydrochloride (3 X 2 tablets daily)
Study: 28335837
Drug: Potent P2Y12
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent P2Y12 inhibitors (prasugrel, ticagrelor, intravenous cangrelor)
Study: 15143715
Drug: S-adenosy-L-methionine (SAM)
Normalized name: L-methionine-S,R-sulfoximine
DrugBank: Methionine sulfoximine (DB14103)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosy-L-methionine (SAM)
Study: 9209184
Drug: Carbohydrate supplementation
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate supplementation (0.75 L carbohydrate beverage, 0.25 L every 15 min during running)
Study: 9209184
Drug: Placebo (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.75 L placebo beverage, 0.25 L every 15 min during running)
Study: 8094467
Drug: Taxol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol (250 mg/m2 by 24-hour intravenous infusion every 3 weeks)
Study: 8094467
Drug: Merbarone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merbarone (1000 mg/m2 by continuous intravenous infusion daily for 5 days every 3 weeks)
Study: 8094467
Drug: Piroxantrone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxantrone (150 mg/m2 by intravenous infusion over 1 hour every 3 weeks)
Study: 2887097
Drug: Nifedipine (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (in patients already receiving beta blockers)
Study: 27333620
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone combined with rhTPO
Study: 27333620
Drug: Single high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single high-dose dexamethasone
Study: 25192026
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Zn/day (experimental group)
Study: 21283046
Drug: Interrupted sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted sedation protocol (midazolam bolus of 0.1 mg/kg, followed by infusion with daily interruption)
Study: 21283046
Drug: Continuous sedation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous sedation protocol (midazolam bolus of 0.1 mg/kg, followed by continuous infusion)
Study: 15972728
Drug: Trimethoprim 300
Normalized name: trimethoprim 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 300 mg daily for three days
Study: 12579169
Drug: Timolol/dorzolamide fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol/dorzolamide fixed combination
Study: 21780543
Drug: Intracervical dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intracervical dinoprostone 0.5 mg
Study: 16916334
Drug: Theophylline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (100 mg b.i.d.)
Study: 12776806
Drug: Test cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test cyclosporine non-SMEDDS formulation
Study: 12776806
Drug: Cyclopsorine SMEDDS
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclopsorine SMEDDS formulation
Study: 9887161
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (3 g [1200 mg of elemental calcium] daily)
Study: 7536831
Drug: Atole (163
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atole (163 kcal/682 kJ, 11.5 g protein per cup)
Study: 7536831
Drug: Fresco (59
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresco (59 kcal/247 kJ, 0 g protein per cup)
Study: 2109473
Drug: Flumazenil 1
Normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 1 mg (Group B)
Study: 6993588
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G treatment
Study: 6175803
Drug: Alinidine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 80 mg
Study: 6849740
Drug: Hydralazine 50
Normalized name: hydralazine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine 50 mg
Study: 6849740
Drug: Alinidine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine 80 mg combined with Hydralazine 50 mg
Study: 6849740
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg combined with Hydralazine 50 mg
Study: 22536858
Drug: Standard topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard topical lidocaine‐4% cream and 99mTc‐sulfur colloid injection
Study: 22536858
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream and 99mTc‐sulfur colloid injection containing NaHCO3
Study: 10503752
Drug: Carbohydrate ingestion
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate ingestion (4 kcal x kg(-1) oral carbohydrate beverage)
Study: 1922863
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg P.O. the evening before surgery
Study: 1922863
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg P.O. the evening before surgery
Study: 1922863
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg I.M. 90 min before induction of anaesthesia
Study: 1922863
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug with H2‐antagonist effect
Study: 10892417
Drug: Beta-agonists
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-agonists
Study: 29771804
Drug: Preemptive analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preemptive analgesia (oral acetaminophen and gabapentin followed by intravenous ketamine and dexamethasone)
Study: 29771804
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral placebos)
Study: 26406550
Drug: Symptomatic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic and supportive treatments (group B)
Study: 22295819
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy in dog days (group A)
Study: 22295819
Drug: Acupoint sticking
Normalized name: Zit Stick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint sticking therapy in non-dog days (group B)
Study: 20972736
Drug: Gliclazide plus
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide plus metformin (GLIMET)
Study: 20972736
Drug: Metformin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin alone (MET)
Study: 17110073
Drug: Soy-based formulation
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based formulation containing pure soy standardized extract of isoflavones
Study: 17110073
Drug: Soy-based formulation
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy-based formulation containing soy flour in addition to the standardized extract of isoflavones
Study: 17110073
Drug: Equol producers
Normalized name: equol, (+-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equol producers with equol excretion added to daidzein excretion
Study: 15677794
Drug: Repaglinide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repaglinide (1 mg twice a day)
Study: 15677794
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg twice a day)
Study: 16009690
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg twice daily
Study: 2270941
Drug: Human isophane
Normalized name: Human isophane insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human isophane insulin